文献速递临床试验与 GCP流行病学与生物统计

识别可能从抗生素治疗中获益的急性鼻窦炎儿童:一项随机临床试验

Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项随机临床试验纳入515例2至11岁临床诊断急性鼻窦炎的儿童,比较口服阿莫西林克拉维酸钾与安慰剂10天的症状负担。结果显示抗生素组平均症状评分9.04 vs 安慰剂组10.60,组间差异-1.69;未检出鼻咽部致病菌的儿童获益小于检出者,组间差异-0.88 vs -1.95;疗效不受鼻分泌物颜色影响。

要点

  • 抗生素组平均症状评分9.04 vs 安慰剂组10.60,组间差异-1.69(95%CI -2.07至-1.31)。
  • 未检出鼻咽部致病菌儿童的症状评分组间差异-0.88,小于检出者的-1.95。
  • 有色鼻分泌物与清亮鼻分泌物的组间差异分别为-1.62与-1.70,交互作用P=0.52。

核心结论

  • 在急性鼻窦炎儿童中,抗生素治疗对就诊时鼻咽部未检出细菌病原体者获益很小,且疗效不取决于鼻分泌物颜色。
  • 作者认为,就诊时检测特定细菌可能代表一种减少该病症抗生素使用的策略。

研究设计与样本

  • 随机临床试验,纳入515例基于临床标准诊断的2至11岁急性鼻窦炎儿童。
  • 试验于2016年2月至2022年4月在美国6所机构附属的初级保健诊所进行。
  • 设计旨在评估按鼻咽部肺炎链球菌、流感嗜血杆菌或卡他莫拉菌培养结果以及有色鼻分泌物分组的亚组间症状负担差异。

主要发现

  • 510例纳入儿童中多数为2至5岁(64%)、男性(54%)、白人(52%)、非西班牙裔(89%)。
  • 阿莫西林克拉维酸钾组平均症状评分9.04(95%CI 8.71至9.37)vs 安慰剂组10.60(95%CI 10.27至10.93),组间差异-1.69(95%CI -2.07至-1.31)。
  • 抗生素组症状缓解时间7.0天 vs 安慰剂组9.0天(P=0.003)。
  • 未检出鼻咽部病原体者平均症状评分组间差异-0.88(95%CI -1.63至-0.12)vs 检出病原体者-1.95(95%CI -2.40至-1.51)。
  • 有色鼻分泌物者组间差异-1.62(95%CI -2.09至-1.16)vs 清亮鼻分泌物者-1.70(95%CI -2.38至-1.03),治疗分组与有色鼻分泌物交互作用P=0.52。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The large overlap between symptoms of acute sinusitis and viral upper respiratory tract infection suggests that certain subgroups of children being diagnosed with acute sinusitis, and subsequently treated with antibiotics, derive little benefit from antibiotic use. OBJECTIVE: To assess if antibiotic therapy could be appropriately withheld in prespecified subgroups. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial including 515 children aged 2 to 11 years diagnosed with acute sinusitis based on clinical criteria. The trial was conducted between February 2016 and April 2022 at primary care offices affiliated with 6 US institutions and was designed to evaluate whether symptom burden differed in subgroups defined by nasopharyngeal Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis on bacterial culture and by the presence of colored nasal discharge. INTERVENTIONS: Oral amoxicillin (90 mg/kg/d) and clavulanate (6.4 mg/kg/d) (n = 254) or placebo (n = 256) for 10 days. MAIN OUTCOMES AND MEASURES: The primary outcome was symptom burden based on daily symptom scores on a validated scale (range, 0-40) during the 10 days after diagnosis. Secondary outcomes included treatment failure, adverse events including clinically significant diarrhea, and resource use by families. RESULTS: Most of the 510 included children were aged 2 to 5 years (64%), male (54%), White (52%), and not Hispanic (89%). The mean symptom scores were significantly lower in children in the amoxicillin and clavulanate group (9.04 [95% CI, 8.71 to 9.37]) compared with those in the placebo group (10.60 [95% CI, 10.27 to 10.93]) (between-group difference, -1.69 [95% CI, -2.07 to -1.31]). The length of time to symptom resolution was significantly lower for children in the antibiotic group (7.0 days) than in the placebo group (9.0 days) (P = .003). Children without nasopharyngeal pathogens detected did not benefit from antibiotic treatment as much as those with pathogens detected; the between-group difference in mean symptom scores was -0.88 (95% CI, -1.63 to -0.12) in those without pathogens detected compared with -1.95 (95% CI, -2.40 to -1.51) in those with pathogens detected. Efficacy did not differ significantly according to whether colored nasal discharge was present (the between-group difference was -1.62 [95% CI, -2.09 to -1.16] for colored nasal discharge vs -1.70 [95% CI, -2.38 to -1.03] for clear nasal discharge; P = .52 for the interaction between treatment group and the presence of colored nasal discharge). CONCLUSIONS: In children with acute sinusitis, antibiotic treatment had minimal benefit for those without nasopharyngeal bacterial pathogens on presentation, and its effects did not depend on the color of nasal discharge. Testing for specific bacteria on presentation may represent a strategy to reduce antibiotic use in this condition. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02554383.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Shaikh N, Hoberman A, Shope TR, et al. Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical Trial. JAMA. 2023. PMID: 37490085. doi:10.1001/jama.2023.10854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。